SAN FRANCISCO – Celgene Corp. kicked off the J.P. Morgan Healthcare Conference Monday morning with a long-term financial outlook that combines the firm's tradition of conservative guidance, while placing emphasis on growing sales of top-selling drug Revlimid (lenalidomide) and a host of promising partnered programs, all with the projection of nearly tripling sales numbers by the year 2020.